Nephrology focuses on diagnosing and treating kidney diseases. The kidneys filter waste, balance fluids, regulate blood pressure, and manage acute and chronic conditions.
Send us all your questions or requests, and our expert team will assist you.
When urinary biomarkers indicate a problem, the “treatment” is rarely about targeting the biomarker itself. You don’t take a pill to erase albumin from your urine directly. Instead, you treat the underlying condition that is causing the biomarker to appear. The biomarker acts as a gauge—a way to measure if the treatment is working. If the treatment is effective, the levels of the harmful biomarkers should drop.
Most treatment plans include a combination of drugs, changes to daily life, and careful retesting of long-term conditions like diabetes and high blood pressure. Follow-up is the cycle of retesting to see if these interventions are successful. It transforms the biomarker from a diagnostic label into a dynamic tool for managing health over the long term.
The first step in treatment is identifying the driver. If the biomarkers point to diabetic kidney disease, the primary treatment is tighter blood sugar control. This might involve adjusting insulin doses, starting new diabetes medications, or changing diet. By lowering the blood sugar, the toxic stress on the kidney filters is reduced, and the leakage of biomarkers like albumin often slows down.
The focus shifts to antihypertensive therapy if high blood pressure is the cause. Lowering the systemic blood pressure reduces the “pressure washing” effect inside the kidney capillaries. This mechanical relief allows the delicate filters to heal, reducing the amount of protein being forced out into the urine.
There are specific classes of blood pressure medications that are renowned for their ability to lower urinary biomarkers. These are ACE inhibitors (ending in -pril) and ARBs (ending in -sartan).
These drugs do more than just lower blood pressure; they alter the blood flow inside the kidney. They relax the blood vessel leaving the filter, which lowers the internal pressure of the glomerulus. This specific action has been proven to significantly reduce albuminuria. These drugs are often given to people with normal blood pressure who have high urinary biomarkers, especially to protect their kidneys. A newer class of drugs, SGLT2 inhibitors, has also shown remarkable ability to lower biomarkers and protect kidney function in both diabetic and non-diabetic patients.
Follow-up is crucial. A single test tells you where you are; a series of tests tells you where you are going. Doctors typically re-check urinary biomarkers every 3 to 6 months for patients with established kidney disease.
They look for a “trend line.” If the ACR (albumin-to-creatinine ratio) drops by 30% or 50% after starting a new medication, it is a sign of success. This implies that the kidney injury is improving. Conversely, if the numbers continue to rise despite treatment, it signals that the disease is aggressive. Such an outcome prompts the medical team to intensify therapy, perhaps adding a second medication or stricter dietary controls.
Lifestyle changes are a potent form of treatment for abnormal biomarkers.
If biomarkers like NGAL or KIM-1 indicate acute kidney injury (AKI), the treatment is immediate and supportive. This usually happens in a hospital.
The focus is on removing the insult. If a medication is causing the toxicity, it is stopped. If dehydration is the cause, intravenous fluids are given to restore blood flow. The biomarkers are tracked frequently—sometimes daily—to see if the kidney cells are recovering. A drop in these injury markers is a hopeful sign that the acute crisis is passing and the organ is healing.
Primary care doctors often handle mild biomarker abnormalities. However, certain thresholds trigger a referral to a nephrologist (kidney specialist).
If the biomarkers show “nephrotic range” proteinuria (very high levels), or if there is blood in the urine combined with high protein, the condition favors a more complex disease like glomerulonephritis. A nephrologist may need to perform a kidney biopsy to obtain a closer look. They will also manage the more complex immunosuppressive treatments if an autoimmune disease is driving the biomarker elevation. The biomarker level helps triage the patient to the right level of care.
Waiting for test results can be anxious. Patients often worry about their numbers.
Part of the follow-up care involves education and reassurance. Understanding that small fluctuations in biomarkers are normal helps reduce anxiety. Knowing that stable numbers—even if they aren’t zero—can still mean a good prognosis is empowering. The medical team works to interpret these numbers in the context of the patient’s whole life, ensuring that the focus remains on living well, not just chasing a number on a page.
Send us all your questions or requests, and our expert team will assist you.
Yes. In early stages of disease, aggressive treatment can sometimes reverse the damage, causing biomarkers like microalbuminuria to disappear completely.
They likely increased the dose to further lower the protein in your urine. The drug is being used for kidney protection, not just blood pressure.
Drinking water dilutes the urine, but the ratio (ACR) corrects for this. So simply drinking more water won’t “trick” the test or cure the problem.
Ideally, the goal is to get the ACR below 30 mg/g. However, any significant reduction (like dropping from 500 to 300) is considered a treatment success.
High biomarkers indicate risk, not destiny. Many people with high protein levels live their whole lives without ever needing dialysis, provided they manage the condition well.
Your Comparison List (you must select at least 2 packages)
